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Abstract Uncoupling proteins (UCPs) are mitochondrial mem-
brane proton transporters that uncouple respiration from
oxidative phosphorylation by dissipating the proton gradient
across the membrane. We studied the direct effect of several
peroxisome proliferator-activated receptor (PPAR) ligands on
UCP-3 and UCP-2 mRNA expression in C2C12 myotubes for
24 h. In the absence of exogenous fatty acids, treatment of
C2C12 cells with a selective PPARK activator (Wy-14,643) or a
non-selective PPAR activator (bezafibrate) did not affect the
expression of UCP-3 mRNA levels, whereas UCP-2 expression
was slightly increased. In contrast, troglitazone, a thiazolidine-
dione which selectively activates PPARQ, strongly decreased
UCP-3 and UCP-2 mRNA levels. Another thiazolidinedione,
ciglitazone, had the same effect, but to a lower extent, suggesting
that PPARQ activation is involved. Further, the presence of 0.5
mM oleic acid strongly increased UCP-3 mRNA levels and
troglitazone addition failed to block the effect of this fatty acid.
The drop in UCP expression after thiazolidinedione treatment
correlated well with a reduction in PPARK mRNA levels
produced by this drug, linking the reduction in PPARK mRNA
levels with the down-regulation of UCP mRNA in C2C12
myotubes after thiazolidinedione treatment. ß 2000 Federation
of European Biochemical Societies. Published by Elsevier Sci-
ence B.V. All rights reserved.
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1. Introduction
Uncoupling proteins (UCPs) are mitochondrial carriers that
are localized in the inner mitochondrial membrane. They act
by dissipating the proton gradient generated by the respira-
tory chain. As a result, they uncouple respiration from oxida-
tive phosphorylation and convert fuel substrates to heat. Two
recently discovered uncoupling protein genes, UCP-2 and
UCP-3, share a high sequence homology with the gene for
uncoupling protein-1 (UCP-1), which plays an important
role in the control of thermogenesis and is speci¢c for brown
adipose tissue (BAT) [1]. UCP-2 is ubiquitously expressed in
all the tissues examined, whereas UCP-3 is highly expressed
only in skeletal muscle and in BAT [2^6]. The biological func-
tions of UCP-2 and UCP-3 are not well understood. Genetic
studies suggest that these UCPs may be involved in energetic
expenditure [7]. In addition, they seem to be implicated in the
regulation of lipids as fuel substrate in skeletal muscle, since
their mRNA levels are up-regulated by the mobilization of fat
stores in the fasted state. The high levels of free fatty acids
achieved in the fasting have been proposed to be responsible
for the increased UCP-3 expression during starvation [8,9].
The induction of UCP by fatty acids is most probably medi-
ated by the activation of peroxisome proliferator-activated
receptor (PPAR). Three di¡erent PPAR subtypes (K, N/L,
and Q) have been identi¢ed to date. PPARK is expressed pri-
marily in tissues that have a high level of fatty acid catabolism
such as liver, brown fat, kidney, heart and skeletal muscle
[10,11]. PPARL is ubiquitously expressed, whereas PPARQ
has a restricted pattern of expression, mainly in white and
brown adipose tissues [12]. PPARQ is also expressed, although
at low levels, in skeletal muscle [13,14]. PPAR binds to DNA
as a heterodimer with the retinoid X receptor and it is acti-
vated by ligands such as naturally occurring fatty acids, which
are ligands of all three PPAR subtypes [15,16]. In addition to
fatty acids, several synthetic compounds bind and activate
speci¢c PPAR subtypes. Antidiabetic thiazolidinediones (tro-
glitazone, ciglitazone, rosiglitazone) bind and selectively acti-
vate PPARQ [17,18], whereas (4-chloro-6-(2,3-xylidine)-pirimi-
dinylthio)acetic acid (Wy-14,643) is selective for PPARK
[19,20]. In contrast, beza¢brate (BFB) activates PPARK,
PPARQ and PPARL with comparable EC50 values [21].
Here, we report the e¡ects of several PPAR ligands on the
expression of UCP-2 and UCP-3 in C2C12 cells. This system,
in contrast to in vivo studies, allows us to assess the direct
e¡ects of drugs and compounds that regulate UCP expression.
In C2C12 cells, a widely used myocyte cell line, the selective
PPARQ activators troglitazone and ciglitazone strongly re-
pressed UCP-3 and UCP-2 mRNA expression. UCP mRNA
down-regulation correlated well with a PPARK decreased
mRNA expression after thiazolidinedione treatment, suggest-
ing that the impaired expression of this transcription factor
was involved in the e¡ects caused by these antidiabetic drugs.
In the presence of oleic acid in the culture medium, the e¡ects
of troglitazone on UCP and PPARK mRNA levels were re-
versed.
2. Materials and methods
2.1. Chemicals
Troglitazone was kindly provided by Glaxo Wellcome (UK) and
atorvastatin by Parke Davis (Spain). Ciglitazone was from Biomol
(Plymouth Meeting, PA, USA), beza¢brate and oleic acid albumin
were from Sigma (St. Louis, MO, USA) and (4-chloro-6-(2,3-xyl-
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idine)-pirimidinylthio)acetic acid (Wy-14,643) was from Cayman
Chemicals (Ann Arbor, MI, USA).
2.2. Cell culture
Mouse C2C12 myoblasts (ATCC) were maintained in Dulbecco’s
modi¢ed Eagle’s medium (DMEM) supplemented with 10% fetal calf
serum (FCS), 50 units/ml penicillin and 50 Wg/ml streptomycin. When
cells reached con£uence, the medium was switched to the di¡erentia-
tion medium containing DMEM and 2% horse serum, which was
changed every other day. After 4 additional days, the di¡erentiated
C2C12 cells had fused into myotubes, which were then treated in
serum-free DMEM with either vehicle (0.1% DMSO) or the drugs
tested for 24 h. After the incubation, RNA was extracted from my-
otubes as described below.
2.3. RNA preparation and analysis
Total RNA was isolated by using the Ultraspec reagent (Biotecx).
Relative levels of speci¢c mRNAs were assessed by the reverse tran-
scription-polymerase chain reaction (RT-PCR). Complementary
DNA was synthesized from RNA samples by mixing 1 Wg of total
RNA, 125 ng of random hexamers as primers in the presence of
50 mM Tris^HCl bu¡er (pH 8.3), 75 mM KCl, 3 mM MgCl2,
10 mM dithiothreitol, 200 U Moloney murine leukemia virus reverse
transcriptase (Life Technologies), 20 U RNAsin (Life Technologies)
and 0.5 mM of each dNTP (Sigma) in a total volume of 20 Wl. Sam-
ples were incubated at 37‡C for 60 min. A 5 Wl aliquot of the RT
reaction was then used for subsequent PCR ampli¢cation with speci¢c
primers.
Each 25 Wl PCR reaction contained 5 Wl of the RT reaction, 1.2
mM MgCl2, 200 WM dNTPs, 1.25 WCi [32P]dATP (3000 Ci/mmol,
Amersham), 1 unit of Taq polymerase (Ecogen, Barcelona, Spain),
0.5 Wg of each primer and 20 mM Tris^HCl, pH 8.5. To avoid un-
speci¢c annealing, cDNA and Taq polymerase were separated from
primers and dNTPs by using a layer of para⁄n (reaction components
contact only when para⁄n fuses, at 60‡C). The sequences of the sense
and antisense primers used for ampli¢cation were: UCP-3, 5P-
GGAGCCATGGCAGTGACCTGT-3P and 5P-TGTGATGTTGGG-
CCAAGTCCC-3P ; UCP-2, 5P-AACAGTTCTACACCAAGGGC-3P
and 5P-AGCATGGTAAGGGCACAGTG-3P ; M-CPT-I, 5P-TTCA-
CTGTGACCCCAGACGGG-3P and 5P-AATGGACCAGCCCCAT-
GGAGA-3P ; MCAD, 5P-TCGAAAGCGGCTCACAAGCAG-3P and
5P-CACCGCAGCTTTCCGGAATGT-3P ; PPARK, 5P-GGCTCGGA-
GGGCTCTGTCATC-3P and 5P-ACATGCACTGGCAGCAGTG-
GA-3P ; PPARL, 5P-GAGGAAGTGGCCACGGGTGAC-3P and 5P-
CCACCTGAGGCCCCATCACAG-3P ; PPARQ, 5P-TGGGGATG-
TCTCACAATGCCA-3P and 5P-TTCCTGTCAAGATCGCCCTCG-
3P ; and APRT (adenosyl phosphoribosyl transferase), 5P-AGCTT-
CCCGGACTTCCCCATC-3P and 5P-GACCACTTTCTGCCCCG-
GTTC-3P. PCR was performed in an MJ Research Thermocycler
equipped with a peltier system and temperature probe. After an initial
denaturation for 1 min at 94‡C, PCR was performed for 20 (MCAD),
21 (UCP-2), 26 (UCP-3), 27 (PPARK, L and Q) or 33 (M-CPT-I)
cycles. Each cycle consisted of denaturation at 92‡C for 1 min, primer
annealing at 60‡C, and primer extension at 72‡C for 1 min and 50 s. A
¢nal 5 min extension step at 72‡C was performed. Five microliters of
each PCR sample was electrophoresed on a 1 mm thick 5% poly-
acrylamide gel. The gels were dried and subjected to autoradiography
using Kodak X-ray ¢lms to show the ampli¢ed DNA products. Am-
pli¢cation of each gene yielded a single band of the expected size
(UCP-3: 179 bp, UCP-2: 471 bp, M-CPT-I: 222 bp, MCAD: 216
bp, PPARK : 645 bp, PPARL : 142 bp, PPARQ : 200 bp, APRT: 329
bp). Preliminary experiments were carried out with various amounts
of cDNA to determine non-saturating conditions of PCR ampli¢ca-
tion for all the genes studied. Thus cDNA ampli¢cation was per-
formed in comparative and semiquantitative conditions. Radioactive
bands were quanti¢ed by video densitometric scanning (Vilbert Lour-
mat Imaging). The results for the expression of speci¢c mRNAs are
always presented relative to the expression of the control gene (aprt).
2.4. Statistical analyses
Results are usually expressed as means þ S.D. of three experiments.
Signi¢cant di¡erences were established by Student’s t-test or ANOVA,
according to the number of groups compared. When signi¢cant var-
iations were found, the Tukey^Kramer multiple comparisons test was
Fig. 1. E¡ects of beza¢brate, Wy-14,643 and troglitazone on the expression of UCP-3 (A), UCP-2 (B), M-CPT-I (C), and MCAD (D) mRNA
in C2C12 myotubes. Cells were incubated for 24 h with vehicle, 500 WM beza¢brate, 10 WM Wy-14,643 or 5 WM troglitazone. 0.5 Wg of total
RNA was analyzed by RT-PCR. A representative autoradiogram and the quanti¢cation of the aprt-normalized mRNA levels are shown. Data
are expressed as mean þ S.D. of three experiments. *P6 0.05, **P6 0.01 and ***P6 0.001 compared with control experiments. F.I., fold induc-
tion.
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performed. Simple correlation analysis was used to evaluate the rela-
tionships among UCP and PPARK mRNA levels. All the statistical
analyses were performed using the computer program GraphPad
Instat.
3. Results
3.1. E¡ects of PPAR activators on UCP mRNA levels in
C2C12 myotubes
C2C12 myoblasts di¡erentiated morphologically to fuse
into myotubes when cultured in the presence of 2% horse
serum 4 days after reaching con£uence. The e¡ects of several
PPAR activators on UCP-3 and UCP-2 mRNA expression
were assessed in C2C12 myotubes for 24 h, incubated without
exogenous fatty acids. In these culture conditions, 5 WM tro-
glitazone, a selective PPARQ activator [17,18], strongly de-
creased UCP-3 mRNA levels by 88% (P6 0.001), whereas
neither beza¢brate, a non-selective PPAR activator [21] used
at a concentration within the plasma levels of ¢brates reported
in humans [22], nor Wy-14,643, which at 10 WM binds and
activates only the PPARK subtype [21], modi¢ed UCP-3
mRNA expression (Fig. 1A). Similarly to UCP-3, UCP-2
mRNA levels decreased by 88% (P6 0.001) after the addition
of troglitazone to C2C12 myotubes. In contrast, treatment
with beza¢brate and Wy-14,643 caused a 1.5- and 1.4-fold
increase in UCP-2 mRNA levels, respectively (Fig. 1B). Since
mitochondrial L-oxidation is involved in the generation of the
electrochemical gradient of protons, which is dissipated by
UCP, we tested whether PPAR activators a¡ected the
mRNA expression of two genes of this system, muscle-type
carnitine palmitoyl transferase (M-CPT-I) and medium-chain
acyl-CoA dehydrogenase (MCAD). The former catalyzes the
entry of long-chain fatty acids into the mitochondrial matrix
[23] and is regulated by PPARK and PPARQ [24]. Of the three
drugs studied, beza¢brate was the only to signi¢cantly change
the expression of M-CPT-I (3-fold induction, P6 0.01) (Fig.
1C). The second, MCAD, catalyzes a rate-limiting step in the
mitochondrial oxidation of medium-chain fatty acyl thioesters
and its transcription is controlled by PPARK [10]. Neither
BFB nor Wy-14,643 a¡ected the MCAD mRNA expression
after 24 h of treatment. Interestingly, addition of troglitazone,
at a concentration (5 WM) known to activate PPARQ, led to a
70% reduction in the mRNA expression of MCAD (Fig. 1D).
3.2. E¡ects of triacsin C and atorvastatin on UCP mRNA
levels in C2C12 myotubes
Troglitazone, in addition to its e¡ects mediated through
PPARQ activation, possesses several additional e¡ects that
are independent of this transcription factor. Thus, it has
been reported that in hepatocytes it reduces fatty acid oxida-
tion through inhibition of acyl-CoA synthetase (ACS) activity
[25]. Further, it has been shown that troglitazone strongly
inhibits cholesterol biosynthesis in muscle cells [26]. In order
to study the contribution of these mechanisms to the e¡ects of
troglitazone, we assessed the e¡ects of triacsin C, a potent
inhibitor of ACS activity, and atorvastatin, an inhibitor of
the cholesterol biosynthesis, on UCP-3 mRNA levels. Addi-
tion of 5 WM triacsin C, a concentration previously reported
Fig. 2. E¡ects of triacsin C (A), cholesterol and atorvastatin (B) on
the expression of UCP-3 mRNA levels in C2C12 myotubes. Cells
were incubated for 24 h with vehicle, 5 WM triacsin C, cholesterol
(10 Wg/ml) or 5 WM atorvastatin. 0.5 Wg of total RNA was analyzed
by RT-PCR. A representative autoradiogram and the quanti¢cation
of the aprt-normalized mRNA levels are shown. Data are expressed
as mean þ S.D. of three experiments. *P6 0.05, **P6 0.01 and
***P6 0.001 compared with control experiments. F.I., fold induc-
tion.
Fig. 3. E¡ects of ciglitazone on the expression of UCP-3 (A), UCP-
2 (B) and MCAD (C) mRNA in C2C12 myotubes. Cells were incu-
bated for 24 h with vehicle or 5 WM ciglitazone. 0.5 Wg of total
RNA was analyzed by RT-PCR. A representative autoradiogram
and the quanti¢cation of the aprt-normalized mRNA levels are
shown. Data are expressed as mean þ S.D. of three experiments.
*P6 0.05, **P6 0.01 and ***P6 0.001 compared with control ex-
periments. F.I., fold induction.
Fig. 4. E¡ects of oleic acid on the expression of UCP-3 mRNA in
C2C12 myotubes. Cells were incubated for 24 h with vehicle or
0.5 mM oleic acid complexed to BSA, in the absence or presence of
5 WM troglitazone. 0.5 Wg of total RNA was analyzed by RT-PCR.
A representative autoradiogram and the quanti¢cation of the aprt-
normalized mRNA levels are shown. Data are expressed as mean þ
S.D. of three experiments. *P6 0.05, **P6 0.01 and ***P6 0.001
compared with control experiments. F.I., fold induction.
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to inhibit ACS [27], resulted in a 1.8-fold induction of UCP-3
mRNA expression (P6 0.01), which is consistent with the
activation of PPARK by free fatty acids [28] (Fig. 2A). The
down-regulation of UCP-3 mRNA levels caused by troglita-
zone was not reversed by the addition of cholesterol (10 Wg/
ml) (Fig. 2B). Likewise, 5 WM atorvastin, a concentration
reported to inhibit cholesterol biosynthesis [29], did not mod-
ify UCP-3 mRNA levels in C2C12 cells.
3.3. E¡ects of ciglitazone on UCP-3 and MCAD mRNA levels
in C2C12 myotubes
In order to determine whether the e¡ects of troglitazone on
UCP expression were speci¢c of this compound or can be
extended to other thiazolidinediones, we tested the e¡ect of
ciglitazone, another compound of this class of antidiabetic
drugs. After 24 h of treatment, ciglitazone decreased the
UCP-3 mRNA expression by 68% (P6 0.01) (Fig. 3A) and
UCP-2 mRNA expression by 63% (P6 0.05) (Fig. 3B), where-
as MCAD mRNA levels were not signi¢cantly decreased (Fig.
3C). These results suggests that ciglitazone had a lesser po-
tency than troglitazone.
3.4. E¡ects of oleic acid on UCP-3 mRNA levels in C2C12
myotubes
It has been shown that addition of oleic acid to C2C12 cells
results in up-regulation of UCP-3 mRNA levels [30]. Maximal
induction (8-fold) of UCP-3 mRNA levels was reported be-
tween 0.6 and 0.9 mM of oleic acid, which approximates the
level of fatty acids in the blood of fasted rats [31]. To test
whether fatty acids reverse the e¡ect evoked by troglitazone
on UCP-3 mRNA expression, we treated C2C12 cells with
0.5 mM oleic acid. As shown in Fig. 4, oleic acid addition
caused a 9.2-fold induction in UCP-3 mRNA levels and abol-
ished the e¡ect of troglitazone (Fig. 4).
3.5. E¡ects of PPAR activators on PPARK, L and Q mRNA
levels in C2C12 myotubes
Finally, we determined the e¡ects of the several PPAR ac-
tivators used in this study on the mRNA levels of PPARK, L
and Q. In contrast to L6 myotubes [32], which only express
PPARL mRNA, C2C12 myotubes express transcripts of the
three PPAR subtypes. Regarding PPARK mRNA levels, be-
za¢brate treatment caused a 48% reduction (P6 0.01), Wy-
14,643 did not a¡ect its expression, whereas troglitazone de-
creased it by 70% (P6 0.001) (Fig. 5A). These results suggest
that impaired expression of PPARK was involved in the ef-
fects caused by thiazolidinediones. In fact, a high correlation
coe⁄cient was obtained when we performed linear regression
between UCP-2 and PPARK (r2 = 0.94, P = 0.0013, n = 6) and
between UCP-3 and PPARK mRNA levels (r2 = 0.84,
P = 0.010, n = 6). None of the PPAR activators studied modi-
¢ed the mRNA expression of PPARL or PPARQ (Fig. 5B and
C). The e¡ects of troglitazone on PPARK mRNA levels were
reversed by the addition of oleic acid (Fig. 6A). Similarly to
Fig. 5. E¡ects of beza¢brate, Wy-14,643 and troglitazone on the expression of PPARK (A), PPARL (B) and PPARQ (C) mRNA in C2C12 my-
otubes. Cells were incubated for 24 h with vehicle, 500 WM beza¢brate, 10 WM Wy-14,643 or 5 WM troglitazone. 0.5 Wg of total RNA was ana-
lyzed by RT-PCR. A representative autoradiogram and the quanti¢cation of the aprt-normalized mRNA levels are shown. Data are expressed
as mean þ S.D. of three experiments. *P6 0.05, **P6 0.01 and ***P6 0.001 compared with control experiments. F.I., fold induction.
Fig. 6. E¡ects of oleic acid (A) and ciglitazone (B) on the expres-
sion of PPARK mRNA in C2C12 myotubes. Cells were incubated
for 24 h with vehicle, 0.5 mM oleic acid complexed to BSA, in the
absence or presence of 5 WM troglitazone or 5 WM ciglitazone.
0.5 Wg of total RNA was analyzed by RT-PCR. A representative
autoradiogram and the quanti¢cation of the aprt-normalized
mRNA levels are shown. Data are expressed as mean þ S.D. of
three experiments. *P6 0.05, **P6 0.01 and ***P6 0.001 compared
with control experiments. F.I., fold induction.
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troglitazone, ciglitazone signi¢cantly decreased the PPARK
mRNA expression by 37% (P6 0.05) (Fig. 6B).
4. Discussion
PPARs have been involved in the regulation of UCPs [1],
which is consistent with the presence of several potential per-
oxisome proliferator response elements (PPRE) in the 5P
£anking region of UCP-3 [33] and UCP-2 [34] genes. Interest-
ingly, of the three PPAR subtypes, PPARK seems to play an
important role in UCP-3 regulation in muscle, since it is re-
sponsible for the switch on of UCP-3 at birth [14]. Premature
newborns, which do not express PPARK in muscle, have thus
impaired responsiveness to PPARK activators [14]. The
present study shows that thiazolidinediones, in the absence
of exogenous fatty acids, down-regulate the mRNA expres-
sion of UCP-3 and UCP-2 in C2C12 cells through impairment
of PPARK expression. The down-regulation of UCP-3 and
UCP-2 by thiazolidinediones correlates well with a reduced
expression in PPARK mRNA levels, suggesting that impaired
expression of this transcription factor was involved in the
e¡ects caused by these antidiabetic drugs.
The mechanism by which troglitazone down-regulates UCP
mRNA expression seems to involve PPARQ activation but not
additional e¡ects not related to PPARQ activation (inhibition
of fatty acid oxidation and cholesterol biosynthesis). This is
consistent with the fact that ciglitazone, another compound of
thiazolidinedione family, which also activates PPARQ, elicited
the same e¡ects although with lesser intensity, which is in
agreement with the lower potency of ciglitazone in activating
PPARQ [26]. In fact, ciglitazone reduced PPARK mRNA ex-
pression by only 37%, whereas troglitazone reduced it by 75%.
This slighter reduction in PPARK mRNA expression caused
by ciglitazone reduced UCP-3 and UCP-2 mRNA levels,
whereas MCAD expression was not signi¢cantly a¡ected.
BFB, which activates the three PPAR subtypes [21], signi¢-
cantly reduced PPARK mRNA levels, probably by activating
the PPARQ subtype. However, no reduction was observed in
UCP-3, UCP-2 or MCAD mRNA levels after BFB treatment,
showing that PPARK activation by BFB can compensate its
reduced expression. BFB increased M-CPT-I mRNA levels,
whereas Wy-14,643 had no e¡ect, suggesting that this induc-
tion could be associated with the reported inhibition of M-
CPT-I by BFB [35] but not with PPARK activation. In agree-
ment to this hypothesis, etomoxir, a well-known inhibitor of
this enzyme activity, up-regulates M-CPT-I mRNA levels in
C2C12 cells (data not shown).
Wy-14,643 treatment for 24 h did not modify mRNA levels
of MCAD, a well-known PPARK target gene [10]. This is
consistent with a previous study, which reported that
MCAD mRNA levels were not induced in the heart of mice
treated with the PPARK activator etomoxir for 24 h [36].
However, in the same study a longer treatment with etomoxir
for 5 days induced MCAD mRNA levels. Therefore, it is
likely that longer times of treatment of C2C12 cells with
PPARK activators would result in the induction of mRNA
levels of this PPARK target gene.
In contrast to the present study, it has been reported that
another thiazolidinedione, rosiglitazone (BRL49653), strongly
increased UCP-3 mRNA levels in C2C12 cells [30]. This dis-
crepancy may be attributed to the higher PPARQ binding
potency of rosiglitazone compared to troglitazone [37] or to
di¡erential activation of PPARQ by troglitazone and rosiglita-
zone, as recently reported [38]. Indeed, troglitazone acted as a
partial agonist for PPARQ in transfected C2C12 cells, produc-
ing a submaximal transcriptional response compared with ro-
siglitazone. Further, troglitazone antagonized rosiglitazone-
stimulated PPARQ transcriptional activity. In another study,
troglitazone treatment did not modify UCP-3 mRNA levels in
L6 myotubes [32]. This lack of e¡ect of troglitazone on L6
myotubes compared to C2C12 cells was attributed to the ab-
sence of PPARQ in the former. In the present work, troglita-
zone treatment for 24 h did not change PPARQ expression,
which is in contrast to the 2.5-fold induction reported in
PPARQ mRNA levels after 4 days of treatment in human
skeletal muscle cells [39]. Although di¡erences in the cellular
type might be the reason of this discrepancy, it is likely that
longer treatments of C2C12 with thiazolidinediones may re-
sult in PPARQ up-regulation.
Here, thiazolidinediones down-regulated UCP expression in
C2C12 cells in the absence of exogenous fatty acids, but in the
presence of glucose in the culture media. When oleic acid was
added to the cells, a strong induction was observed in UCP-3
mRNA levels, similarly to previous studies [30], and troglita-
zone did not reverse this induction. UCP-3 down-regulation
has been reported in vivo after thiazolidinedione treatment
(pioglitazone) in skeletal muscle of hyperglycemic KK mice
[40]. In this study, a high correlation was found between re-
duced glucose plasma levels and UCP-3 down-regulation,
whereas plasma free fatty acids were not reported. Since thia-
zolidinediones improve the use of glucose as substrate [41],
when glucose is the main substrate available, these drugs
may strongly increase the use of glucose and decrease the
expression of UCP. In contrast, when fatty acids are present
in the media, they are used, leading to increased expression of
UCP. In these conditions it is believed that UCP up-regula-
tion may be involved in adaptation of cellular metabolism to
an excessive supply of lipid substrates in order to regulate the
ATP level, the NAD/NADH ratio and to contain superoxide
production [1].
In summary, thiazolidinediones down-regulate the expres-
sion of UCP-3 and UCP-2 mRNA levels in C2C12 myotubes
cultured in the absence of exogenous fatty acids. The decrease
in UCP expression correlated well with an impaired expres-
sion of PPARK mRNA levels. In the presence of oleic acid,
UCP-3 expression was up-regulated and thiazolidinediones
did not reverse this induction. Although further evidence is
required, these results suggest that the presence of di¡erent
fuel substrates in the culture media modi¢es the e¡ects of
PPAR ligands on UCP expression.
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